Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 26;119(31):e2205042119. doi: 10.1073/pnas.2205042119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 the Author(s). Published by PNAS

This article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

PMC Copyright notice

Fig. 1. — DMF treatment changes the peripheral immune profile of MS. (A) Blood samples and clinical data from a cohort of MS patients (n = 31, as well as two validation cohorts) before the initiation of DMF therapy and at 3- and 12-mo follow-up were longitudinally collected and analyzed for immune profile by mass cytometry and SNPs by DNA microarray. (B) UMAP representation of analyzed peripheral blood immune cells with overlaid color code as categorized by FlowSOM-defined clusters. (C) Immune compartments as defined by FlowSOM-defined clusters. Mean expression profile of all analyzed parameters in each defined population. (D) Longitudinal frequencies of the immune populations in blood in relative numbers. (E) Longitudinal cell counts of the main immune populations in blood in absolute numbers.